(Q37974998)

26 August 2017

title

The hidden third: improving outcome in treatment-resistant depression (English)

1 reference

26 August 2017

1

1 reference

26 August 2017

8

Siegfried Kasper

0 references

David Nutt

7

object named as

David J Nutt

0 references

Palmiero Monteleone

3

object named as

Palmiero Monteleone

1 reference

26 August 2017

Hans Agren

2

1 reference

26 August 2017

Cristobal Gasto

4

1 reference

26 August 2017

William Pitchot

5

1 reference

26 August 2017

Frederick Rouillon

6

1 reference

26 August 2017

language of work or name

English

0 references

publication date

11 January 2012

1 reference

Journal of Psychopharmacology

26 August 2017

published in

1 reference

26 August 2017

volume

26

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

587-602

1 reference

Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Objective: remission of depression in primary care The Oreon Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthre

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

An update on regional brain volume differences associated with mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Augmentation strategies for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Reducing the societal burden of depression: a review of economic costs, quality of care and effects of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled st

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Diagnosis and definition of treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Pharmacologic management of difficult-to-treat depression in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

[Use of electroconvulsive therapy in psychiatry].

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Transcranial magnetic stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

A controlled trial of daily left prefrontal cortex TMS for treating depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Toward an anti-inflammatory strategy for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Therapy of treatment resistant depression: focus on the management of TRD with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Mechanisms and state of the art of vagus nerve stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Overview of the Genetics of Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Deep brain stimulation for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Disruption of the circadian timing systems: molecular mechanisms in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Treatments of depression and the functional capacity to work.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Antidepressant-like actions of minocycline combined with several glutamate antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

The circadian basis of mood disorders: recent developments and treatment implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Depression, chronic diseases, and decrements in health: results from the World Health Surveys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

COX-2 inhibition in schizophrenia and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

The other face of depression, reduced positive affect: the role of catecholamines in causation and cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Comorbid alcohol and substance abuse dependence in depression: impact on the outcome of antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Efficacy of ECT in depression: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Empirical testing of two models for staging antidepressant treatment resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Medication resistance and clinical response to electroconvulsive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Challenges in the treatment of depression with psychotic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

WFSBP Guidelines on Brain Stimulation Treatments in Psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Deep brain stimulation for treatment of refractory depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

[Combining antidepressants: a useful strategy for therapy resistant depression?].

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Managing the patient with co-morbid depression and an anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Therapeutic options for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Stigma as a barrier to recovery: Perceived stigma and patient-rated severity of illness as predictors of antidepressant drug adherence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Invited review: the evolution of antidepressant mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Treatment resistant depression: methodological overview and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Genetic epidemiology of major depression: review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Deep brain stimulation: neuropsychological and neuropsychiatric issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Efficacy and side effects of mianserin, a tetracyclic antidepressant

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

The STAR*D Project results: a comprehensive review of findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Relapse prevention in major depressive disorder after successful ECT: a literature review and a naturalistic case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

A prospective follow-up of patients with bipolar and primary unipolar affective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

A double-blind, placebo-controlled study of memantine in the treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

Remission in depressed outpatients: more than just symptom resolution?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431748

21 January 2018

Identifiers

DOI

10.1177/0269881111431748

1 reference

release_ivhc7hf3grcd5eoh34e24n3ra4

26 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ivhc7hf3grcd5eoh34e24n3ra4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference